JP2021502361A - 共有エピトープ−カルレティキュリン相互作用の小分子阻害薬及び使用方法 - Google Patents
共有エピトープ−カルレティキュリン相互作用の小分子阻害薬及び使用方法 Download PDFInfo
- Publication number
- JP2021502361A JP2021502361A JP2020524852A JP2020524852A JP2021502361A JP 2021502361 A JP2021502361 A JP 2021502361A JP 2020524852 A JP2020524852 A JP 2020524852A JP 2020524852 A JP2020524852 A JP 2020524852A JP 2021502361 A JP2021502361 A JP 2021502361A
- Authority
- JP
- Japan
- Prior art keywords
- disease
- bone
- dermatitis
- patient
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003993 interaction Effects 0.000 title claims abstract description 28
- 150000003384 small molecules Chemical class 0.000 title abstract description 16
- 239000003112 inhibitor Substances 0.000 title description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 114
- 201000010099 disease Diseases 0.000 claims abstract description 58
- 208000035475 disorder Diseases 0.000 claims abstract description 49
- 239000003814 drug Substances 0.000 claims abstract description 44
- 206010003246 arthritis Diseases 0.000 claims abstract description 24
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 19
- 230000027455 binding Effects 0.000 claims abstract description 17
- 208000037976 chronic inflammation Diseases 0.000 claims abstract description 16
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims abstract description 14
- 230000008938 immune dysregulation Effects 0.000 claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims description 127
- 238000000034 method Methods 0.000 claims description 66
- 239000000203 mixture Substances 0.000 claims description 63
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 54
- 210000000988 bone and bone Anatomy 0.000 claims description 34
- 239000008194 pharmaceutical composition Substances 0.000 claims description 31
- 150000003839 salts Chemical class 0.000 claims description 31
- 201000004624 Dermatitis Diseases 0.000 claims description 27
- 229940079593 drug Drugs 0.000 claims description 25
- 230000000694 effects Effects 0.000 claims description 25
- 238000011282 treatment Methods 0.000 claims description 23
- 230000002519 immonomodulatory effect Effects 0.000 claims description 22
- 206010065687 Bone loss Diseases 0.000 claims description 21
- 239000000651 prodrug Substances 0.000 claims description 20
- 229940002612 prodrug Drugs 0.000 claims description 20
- 208000006673 asthma Diseases 0.000 claims description 19
- 206010051728 Bone erosion Diseases 0.000 claims description 17
- 210000001519 tissue Anatomy 0.000 claims description 14
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 13
- 208000001132 Osteoporosis Diseases 0.000 claims description 13
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 12
- 239000003435 antirheumatic agent Substances 0.000 claims description 12
- 230000001684 chronic effect Effects 0.000 claims description 12
- 239000003937 drug carrier Substances 0.000 claims description 12
- 201000004384 Alopecia Diseases 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 11
- 208000015181 infectious disease Diseases 0.000 claims description 10
- 206010023332 keratitis Diseases 0.000 claims description 10
- 210000000056 organ Anatomy 0.000 claims description 10
- 208000028169 periodontal disease Diseases 0.000 claims description 10
- 206010019663 Hepatic failure Diseases 0.000 claims description 9
- 231100000360 alopecia Toxicity 0.000 claims description 9
- 230000003779 hair growth Effects 0.000 claims description 9
- 208000007903 liver failure Diseases 0.000 claims description 9
- 231100000835 liver failure Toxicity 0.000 claims description 9
- 125000006239 protecting group Chemical group 0.000 claims description 9
- 206010015150 Erythema Diseases 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 231100000321 erythema Toxicity 0.000 claims description 8
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 7
- 230000001154 acute effect Effects 0.000 claims description 7
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 7
- 230000002757 inflammatory effect Effects 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 201000000306 sarcoidosis Diseases 0.000 claims description 7
- 239000012453 solvate Substances 0.000 claims description 7
- 238000002054 transplantation Methods 0.000 claims description 7
- 208000009137 Behcet syndrome Diseases 0.000 claims description 6
- 206010016654 Fibrosis Diseases 0.000 claims description 6
- 206010019799 Hepatitis viral Diseases 0.000 claims description 6
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims description 6
- 206010020751 Hypersensitivity Diseases 0.000 claims description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 206010029240 Neuritis Diseases 0.000 claims description 6
- 206010036105 Polyneuropathy Diseases 0.000 claims description 6
- 208000026935 allergic disease Diseases 0.000 claims description 6
- 208000007502 anemia Diseases 0.000 claims description 6
- 208000010668 atopic eczema Diseases 0.000 claims description 6
- 230000037182 bone density Effects 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 230000007882 cirrhosis Effects 0.000 claims description 6
- 230000009610 hypersensitivity Effects 0.000 claims description 6
- 208000023589 ischemic disease Diseases 0.000 claims description 6
- 208000019629 polyneuritis Diseases 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 208000011580 syndromic disease Diseases 0.000 claims description 6
- 201000001862 viral hepatitis Diseases 0.000 claims description 6
- 201000001320 Atherosclerosis Diseases 0.000 claims description 5
- 208000010392 Bone Fractures Diseases 0.000 claims description 5
- 206010012441 Dermatitis bullous Diseases 0.000 claims description 5
- 206010017076 Fracture Diseases 0.000 claims description 5
- 206010027476 Metastases Diseases 0.000 claims description 5
- 230000003356 anti-rheumatic effect Effects 0.000 claims description 5
- 230000035876 healing Effects 0.000 claims description 5
- 230000001506 immunosuppresive effect Effects 0.000 claims description 5
- 230000009401 metastasis Effects 0.000 claims description 5
- 238000003860 storage Methods 0.000 claims description 5
- 230000009885 systemic effect Effects 0.000 claims description 5
- 208000011231 Crohn disease Diseases 0.000 claims description 4
- 206010014950 Eosinophilia Diseases 0.000 claims description 4
- 208000003084 Graves Ophthalmopathy Diseases 0.000 claims description 4
- 206010020850 Hyperthyroidism Diseases 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 4
- 230000001363 autoimmune Effects 0.000 claims description 4
- 150000001540 azides Chemical class 0.000 claims description 4
- 210000000987 immune system Anatomy 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 230000000302 ischemic effect Effects 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 208000030507 AIDS Diseases 0.000 claims description 3
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 3
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 3
- 208000007788 Acute Liver Failure Diseases 0.000 claims description 3
- 208000026872 Addison Disease Diseases 0.000 claims description 3
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 206010002660 Anoxia Diseases 0.000 claims description 3
- 241000976983 Anoxia Species 0.000 claims description 3
- 208000032467 Aplastic anaemia Diseases 0.000 claims description 3
- 206010003559 Asthma late onset Diseases 0.000 claims description 3
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 claims description 3
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims description 3
- 208000035143 Bacterial infection Diseases 0.000 claims description 3
- 208000023328 Basedow disease Diseases 0.000 claims description 3
- 208000005623 Carcinogenesis Diseases 0.000 claims description 3
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 3
- 208000002177 Cataract Diseases 0.000 claims description 3
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims description 3
- 206010009208 Cirrhosis alcoholic Diseases 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 206010010741 Conjunctivitis Diseases 0.000 claims description 3
- 206010011831 Cytomegalovirus infection Diseases 0.000 claims description 3
- 206010012442 Dermatitis contact Diseases 0.000 claims description 3
- 206010014561 Emphysema Diseases 0.000 claims description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 3
- 208000024869 Goodpasture syndrome Diseases 0.000 claims description 3
- 206010018691 Granuloma Diseases 0.000 claims description 3
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 3
- 208000001204 Hashimoto Disease Diseases 0.000 claims description 3
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 3
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 3
- 206010021143 Hypoxia Diseases 0.000 claims description 3
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 claims description 3
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims description 3
- 206010061598 Immunodeficiency Diseases 0.000 claims description 3
- 208000012309 Linear IgA disease Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 208000027530 Meniere disease Diseases 0.000 claims description 3
- 208000019695 Migraine disease Diseases 0.000 claims description 3
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 3
- 208000024599 Mooren ulcer Diseases 0.000 claims description 3
- 206010028372 Muscular weakness Diseases 0.000 claims description 3
- 206010028851 Necrosis Diseases 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 206010030113 Oedema Diseases 0.000 claims description 3
- 206010031252 Osteomyelitis Diseases 0.000 claims description 3
- 206010033645 Pancreatitis Diseases 0.000 claims description 3
- 208000006311 Pyoderma Diseases 0.000 claims description 3
- 206010037779 Radiculopathy Diseases 0.000 claims description 3
- 208000033626 Renal failure acute Diseases 0.000 claims description 3
- 206010063837 Reperfusion injury Diseases 0.000 claims description 3
- 201000007737 Retinal degeneration Diseases 0.000 claims description 3
- 206010048908 Seasonal allergy Diseases 0.000 claims description 3
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims description 3
- 206010039966 Senile dementia Diseases 0.000 claims description 3
- 206010040047 Sepsis Diseases 0.000 claims description 3
- 206010040070 Septic Shock Diseases 0.000 claims description 3
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 3
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 3
- 208000001106 Takayasu Arteritis Diseases 0.000 claims description 3
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 3
- 208000007536 Thrombosis Diseases 0.000 claims description 3
- 206010070863 Toxicity to various agents Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 206010064996 Ulcerative keratitis Diseases 0.000 claims description 3
- 208000024780 Urticaria Diseases 0.000 claims description 3
- 208000001445 Uveomeningoencephalitic Syndrome Diseases 0.000 claims description 3
- 208000024248 Vascular System injury Diseases 0.000 claims description 3
- 208000012339 Vascular injury Diseases 0.000 claims description 3
- 206010047115 Vasculitis Diseases 0.000 claims description 3
- 208000034705 Vogt-Koyanagi-Harada syndrome Diseases 0.000 claims description 3
- 206010000496 acne Diseases 0.000 claims description 3
- 201000011040 acute kidney failure Diseases 0.000 claims description 3
- 208000012998 acute renal failure Diseases 0.000 claims description 3
- 230000032683 aging Effects 0.000 claims description 3
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 claims description 3
- 150000001345 alkine derivatives Chemical class 0.000 claims description 3
- 201000009961 allergic asthma Diseases 0.000 claims description 3
- 230000007953 anoxia Effects 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 3
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 3
- 208000005980 beta thalassemia Diseases 0.000 claims description 3
- 206010006451 bronchitis Diseases 0.000 claims description 3
- 230000036952 cancer formation Effects 0.000 claims description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 3
- 231100000504 carcinogenesis Toxicity 0.000 claims description 3
- 239000004568 cement Substances 0.000 claims description 3
- 238000002512 chemotherapy Methods 0.000 claims description 3
- 208000020832 chronic kidney disease Diseases 0.000 claims description 3
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 3
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims description 3
- 208000010247 contact dermatitis Diseases 0.000 claims description 3
- 230000007850 degeneration Effects 0.000 claims description 3
- 239000000428 dust Substances 0.000 claims description 3
- 238000003912 environmental pollution Methods 0.000 claims description 3
- 230000010437 erythropoiesis Effects 0.000 claims description 3
- 229910052731 fluorine Chemical group 0.000 claims description 3
- 239000011737 fluorine Chemical group 0.000 claims description 3
- 201000005917 gastric ulcer Diseases 0.000 claims description 3
- 206010019692 hepatic necrosis Diseases 0.000 claims description 3
- 208000006454 hepatitis Diseases 0.000 claims description 3
- 231100000283 hepatitis Toxicity 0.000 claims description 3
- 229960001340 histamine Drugs 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 230000003463 hyperproliferative effect Effects 0.000 claims description 3
- 230000004957 immunoregulator effect Effects 0.000 claims description 3
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims description 3
- 201000006334 interstitial nephritis Diseases 0.000 claims description 3
- 230000003903 intestinal lesions Effects 0.000 claims description 3
- 229910052742 iron Inorganic materials 0.000 claims description 3
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims description 3
- 201000010666 keratoconjunctivitis Diseases 0.000 claims description 3
- 208000002741 leukoplakia Diseases 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 231100000149 liver necrosis Toxicity 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 230000003211 malignant effect Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 206010027599 migraine Diseases 0.000 claims description 3
- 230000036473 myasthenia Effects 0.000 claims description 3
- 230000017074 necrotic cell death Effects 0.000 claims description 3
- 208000037931 necrotizing enteritis Diseases 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 230000000414 obstructive effect Effects 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 230000036961 partial effect Effects 0.000 claims description 3
- 230000003239 periodontal effect Effects 0.000 claims description 3
- 201000001245 periodontitis Diseases 0.000 claims description 3
- VUNPWIPIOOMCPT-UHFFFAOYSA-N piperidin-3-ylmethanol Chemical compound OCC1CCCNC1 VUNPWIPIOOMCPT-UHFFFAOYSA-N 0.000 claims description 3
- 208000005987 polymyositis Diseases 0.000 claims description 3
- 230000002685 pulmonary effect Effects 0.000 claims description 3
- 230000005855 radiation Effects 0.000 claims description 3
- 238000002271 resection Methods 0.000 claims description 3
- 208000023504 respiratory system disease Diseases 0.000 claims description 3
- 201000003068 rheumatic fever Diseases 0.000 claims description 3
- 206010039083 rhinitis Diseases 0.000 claims description 3
- 238000007363 ring formation reaction Methods 0.000 claims description 3
- 231100000241 scar Toxicity 0.000 claims description 3
- 208000010157 sclerosing cholangitis Diseases 0.000 claims description 3
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 3
- 230000035939 shock Effects 0.000 claims description 3
- 208000017520 skin disease Diseases 0.000 claims description 3
- 230000008359 toxicosis Effects 0.000 claims description 3
- 239000003053 toxin Substances 0.000 claims description 3
- 231100000765 toxin Toxicity 0.000 claims description 3
- 108700012359 toxins Proteins 0.000 claims description 3
- 230000008733 trauma Effects 0.000 claims description 3
- 230000002485 urinary effect Effects 0.000 claims description 3
- 230000002792 vascular Effects 0.000 claims description 3
- 102000004877 Insulin Human genes 0.000 claims description 2
- 108090001061 Insulin Proteins 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims description 2
- 238000010168 coupling process Methods 0.000 claims description 2
- 238000005859 coupling reaction Methods 0.000 claims description 2
- 238000006264 debenzylation reaction Methods 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 206010003230 arteritis Diseases 0.000 claims 3
- 241000251468 Actinopterygii Species 0.000 claims 2
- 208000025865 Ulcer Diseases 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 208000028774 intestinal disease Diseases 0.000 claims 2
- 231100000397 ulcer Toxicity 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 208000027496 Behcet disease Diseases 0.000 claims 1
- 241000701022 Cytomegalovirus Species 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 206010049466 Erythroblastosis Diseases 0.000 claims 1
- 208000005577 Gastroenteritis Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000003923 Hereditary Corneal Dystrophies Diseases 0.000 claims 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 1
- 206010024380 Leukoderma Diseases 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 201000009623 Myopathy Diseases 0.000 claims 1
- 206010036775 Rectal inflammations Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 230000001668 ameliorated effect Effects 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 210000000941 bile Anatomy 0.000 claims 1
- 210000004087 cornea Anatomy 0.000 claims 1
- 206010011005 corneal dystrophy Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 210000003979 eosinophil Anatomy 0.000 claims 1
- 208000024711 extrinsic asthma Diseases 0.000 claims 1
- 210000003714 granulocyte Anatomy 0.000 claims 1
- 230000002949 hemolytic effect Effects 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 230000006872 improvement Effects 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 230000003658 preventing hair loss Effects 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 208000013223 septicemia Diseases 0.000 claims 1
- 230000007863 steatosis Effects 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 abstract description 18
- 230000019491 signal transduction Effects 0.000 abstract description 10
- 230000002401 inhibitory effect Effects 0.000 abstract description 9
- 206010061218 Inflammation Diseases 0.000 abstract description 5
- 230000004054 inflammatory process Effects 0.000 abstract description 5
- 230000001009 osteoporotic effect Effects 0.000 abstract description 5
- 208000012201 sexual and gender identity disease Diseases 0.000 abstract description 4
- 208000015891 sexual disease Diseases 0.000 abstract description 4
- 206010037211 Psychomotor hyperactivity Diseases 0.000 abstract description 2
- 230000008482 dysregulation Effects 0.000 abstract description 2
- 210000002997 osteoclast Anatomy 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 20
- 239000003795 chemical substances by application Substances 0.000 description 19
- 241000721454 Pemphigus Species 0.000 description 18
- 208000024891 symptom Diseases 0.000 description 18
- 239000007924 injection Substances 0.000 description 16
- 238000002347 injection Methods 0.000 description 16
- -1 (R, E)-(1-((1- (3- (1-methyl-1H-pyrazole-4-yl) acryloyl) piperidine-3-yl) methyl) -1H-1,2,3- Triazole-4-yl) Chemical group 0.000 description 14
- 239000002253 acid Substances 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 230000001225 therapeutic effect Effects 0.000 description 14
- 241000219061 Rheum Species 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- 230000006378 damage Effects 0.000 description 12
- 230000004071 biological effect Effects 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 230000004069 differentiation Effects 0.000 description 11
- 102000004082 Calreticulin Human genes 0.000 description 10
- 108090000549 Calreticulin Proteins 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 230000004913 activation Effects 0.000 description 9
- 239000002585 base Substances 0.000 description 9
- 230000018109 developmental process Effects 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 238000011161 development Methods 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 208000009386 Experimental Arthritis Diseases 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 208000027866 inflammatory disease Diseases 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000011664 signaling Effects 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 0 *c1c[n](C#C[C@](C*C2)CN2C(C=Cc2c(*)[n](*)nc2)=O)nn1 Chemical compound *c1c[n](C#C[C@](C*C2)CN2C(C=Cc2c(*)[n](*)nc2)=O)nn1 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- 239000002260 anti-inflammatory agent Substances 0.000 description 6
- 230000010072 bone remodeling Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 210000001503 joint Anatomy 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 230000000241 respiratory effect Effects 0.000 description 6
- 108700028369 Alleles Proteins 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 238000011260 co-administration Methods 0.000 description 5
- 230000003628 erosive effect Effects 0.000 description 5
- 150000002596 lactones Chemical class 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 description 4
- 108010039343 HLA-DRB1 Chains Proteins 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 102000007591 Tartrate-Resistant Acid Phosphatase Human genes 0.000 description 4
- 108010032050 Tartrate-Resistant Acid Phosphatase Proteins 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000009510 drug design Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 206010025482 malaise Diseases 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 201000008383 nephritis Diseases 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 208000029725 Metabolic bone disease Diseases 0.000 description 3
- 206010027452 Metastases to bone Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 3
- 206010049088 Osteopenia Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 150000001408 amides Chemical group 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000013467 fragmentation Methods 0.000 description 3
- 238000006062 fragmentation reaction Methods 0.000 description 3
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 229960002009 naproxen Drugs 0.000 description 3
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000006072 paste Substances 0.000 description 3
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- 201000010000 Agranulocytosis Diseases 0.000 description 2
- 206010003267 Arthritis reactive Diseases 0.000 description 2
- 206010003645 Atopy Diseases 0.000 description 2
- 208000020084 Bone disease Diseases 0.000 description 2
- 208000018084 Bone neoplasm Diseases 0.000 description 2
- 241000246150 Cercis Species 0.000 description 2
- 235000018893 Cercis canadensis var canadensis Nutrition 0.000 description 2
- 206010009657 Clostridium difficile colitis Diseases 0.000 description 2
- 208000014311 Cushing syndrome Diseases 0.000 description 2
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 2
- 208000034619 Gingival inflammation Diseases 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 206010023232 Joint swelling Diseases 0.000 description 2
- 208000001126 Keratosis Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010027910 Mononeuritis Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 208000003926 Myelitis Diseases 0.000 description 2
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 201000011152 Pemphigus Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 description 2
- 206010037128 Pseudomembranous colitis Diseases 0.000 description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 2
- 206010053879 Sepsis syndrome Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 201000002661 Spondylitis Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 2
- 210000000068 Th17 cell Anatomy 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 206010047626 Vitamin D Deficiency Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000012387 aerosolization Methods 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000000772 anti-erosive effect Effects 0.000 description 2
- 230000000169 anti-osteoclastic effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 208000016738 bone Paget disease Diseases 0.000 description 2
- 238000013276 bronchoscopy Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 229960001259 diclofenac Drugs 0.000 description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 208000021864 drug-induced osteoporosis Diseases 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 208000024963 hair loss Diseases 0.000 description 2
- 230000003676 hair loss Effects 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 150000004679 hydroxides Chemical class 0.000 description 2
- 208000036260 idiopathic disease Diseases 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 208000023569 ischemic bowel disease Diseases 0.000 description 2
- 206010023365 keratopathy Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- GWNVDXQDILPJIG-NXOLIXFESA-N leukotriene C4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-NXOLIXFESA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 210000000878 metatarsophalangeal joint Anatomy 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 208000013734 mononeuritis simplex Diseases 0.000 description 2
- 201000005518 mononeuropathy Diseases 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 201000005962 mycosis fungoides Diseases 0.000 description 2
- CDBRNDSHEYLDJV-FVGYRXGTSA-M naproxen sodium Chemical compound [Na+].C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CDBRNDSHEYLDJV-FVGYRXGTSA-M 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 230000002981 neuropathic effect Effects 0.000 description 2
- 231100000344 non-irritating Toxicity 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 201000001976 pemphigus vulgaris Diseases 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- 150000003009 phosphonic acids Chemical class 0.000 description 2
- 150000008298 phosphoramidates Chemical class 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 159000000001 potassium salts Chemical class 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 208000002574 reactive arthritis Diseases 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000012899 standard injection Substances 0.000 description 2
- 208000001162 steatorrhea Diseases 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 210000001258 synovial membrane Anatomy 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 150000003852 triazoles Chemical class 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- XUJDQACAPGQNDG-GJBLVYBDSA-N CNCc1ncc(C[C@H](CCC2)CN2C(/C=C/c2c[n](C)nc2)=O)[o]1 Chemical compound CNCc1ncc(C[C@H](CCC2)CN2C(/C=C/c2c[n](C)nc2)=O)[o]1 XUJDQACAPGQNDG-GJBLVYBDSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 201000002980 Hyperparathyroidism Diseases 0.000 description 1
- 206010023198 Joint ankylosis Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010031264 Osteonecrosis Diseases 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001111421 Pannus Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 206010061363 Skeletal injury Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000018359 Systemic autoimmune disease Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000001253 acrylic acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 229940072359 anaprox Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- ZBPLOVFIXSTCRZ-UHFFFAOYSA-N bromfenac Chemical compound NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 ZBPLOVFIXSTCRZ-UHFFFAOYSA-N 0.000 description 1
- 229960003655 bromfenac Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229940047495 celebrex Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229940070230 daypro Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 description 1
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 description 1
- KPHWPUGNDIVLNH-UHFFFAOYSA-M diclofenac sodium Chemical compound [Na+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KPHWPUGNDIVLNH-UHFFFAOYSA-M 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940072701 dolobid Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000002310 elbow joint Anatomy 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 229950009769 etabonate Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 229940065410 feldene Drugs 0.000 description 1
- 229960004887 ferric hydroxide Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960001067 hydrocortisone acetate Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000008088 immune pathway Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 229940089536 indocin Drugs 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- IEECXTSVVFWGSE-UHFFFAOYSA-M iron(3+);oxygen(2-);hydroxide Chemical compound [OH-].[O-2].[Fe+3] IEECXTSVVFWGSE-UHFFFAOYSA-M 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 210000001847 jaw Anatomy 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 210000001872 metatarsal bone Anatomy 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229940112801 mobic Drugs 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 229960003940 naproxen sodium Drugs 0.000 description 1
- QEFAQIPZVLVERP-UHFFFAOYSA-N nepafenac Chemical compound NC(=O)CC1=CC=CC(C(=O)C=2C=CC=CC=2)=C1N QEFAQIPZVLVERP-UHFFFAOYSA-N 0.000 description 1
- 229960001002 nepafenac Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000005064 nitric oxide mediated signal transduction Effects 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 229940103453 novolin Drugs 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000001599 osteoclastic effect Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000005547 pivalate group Chemical group 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- NXZGIDGNDLSFDH-UHFFFAOYSA-N prop-2-enoic acid;1h-pyrazole Chemical compound C=1C=NNC=1.OC(=O)C=C NXZGIDGNDLSFDH-UHFFFAOYSA-N 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 108091006084 receptor activators Proteins 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000005558 regulation of bone resorption Effects 0.000 description 1
- 230000026011 regulation of ossification Effects 0.000 description 1
- 229940087462 relafen Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229960000953 salsalate Drugs 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000323 shoulder joint Anatomy 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 210000005222 synovial tissue Anatomy 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 150000003567 thiocyanates Chemical class 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 210000001226 toe joint Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940019127 toradol Drugs 0.000 description 1
- 125000005490 tosylate group Chemical group 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical class CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229940063674 voltaren Drugs 0.000 description 1
- 210000003857 wrist joint Anatomy 0.000 description 1
- UGZADUVQMDAIAO-UHFFFAOYSA-L zinc hydroxide Chemical compound [OH-].[OH-].[Zn+2] UGZADUVQMDAIAO-UHFFFAOYSA-L 0.000 description 1
- 229940007718 zinc hydroxide Drugs 0.000 description 1
- 229910021511 zinc hydroxide Inorganic materials 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
関連出願の相互参照
本出願は、全体が参照により本明細書に組み込まれる2017年11月7日に出願された米国仮特許出願第62/582,584号に対する優先権及び利益を主張する。
本発明は、医薬品化学の分野にある。特に、本発明は、共有エピトープ(SE)−カルレティキュリン(CRT)結合及び/または相互作用のモジュレーターとして機能するトリアゾール−メチル−ピペリジニル−ピロリル−プロペノン構造を有する少分子の新しいクラス、ならびに、関節炎及び/または他の疾患もしくは状態において一般的な過活動または調節不全のSE−CRT相互作用及び/またはシグナル伝達経路を選択的に阻害することにより、免疫調節異常(例えば、自己免疫疾患、炎症性疾患(例えば、慢性炎症性疾患)、及び骨びらん性疾患)を処置するための治療薬としてのその使用に関する。
関節リウマチ(RA)及び歯周病はともに、慢性炎症及び骨びらんを特徴とする(例えば、Bromley and Woolley,Arthritis Rheum.Aug 1984;27:857−863,Fujikawa et al.,Br J Rheumatol.Mar 1996;35:213−217,Gravallese et al.,Arthritis Rheum.Feb 2000;43:250−258,Marotte et al.,Ann Rheum Dis.2006 65:905−909を参照のこと)。両方の疾患は、DRβ鎖の領域70〜74中の『共有エピトープ』(SE)と呼ばれる5つのアミノ酸配列モチーフをコードするHLA−DRB1対立遺伝子と関連する(例えば、Gregersen et al.,Arthritis Rheum.1987;30:1205−1213を参照のこと)。RAでは、SEは、高いリスクを与えるだけでなく、より重症の疾患を発症する可能性を増加させる。同様に、歯周病では、SEは、より深刻な骨破壊に関連する(例えば、Marotte et al.,Ann Rheum Dis.2006 65:905−909を参照のこと)。
〔発明の概要〕
HL840(
)((R,E)−(1−((1−(3−(1−メチル−1H−ピラゾール−4−イル)アクリロイル)ピペリジン−3−イル)メチル)−1H−1,2,3−トリアゾール−4−イル)メタナミニウム)を同定した(例えば、実施例1〜3を参照のこと)。
それらの薬学的に許容される塩、溶媒和物、及び/またはプロドラッグを含む。
(a)構造:
を有する化合物を調製するための、ピペリジン−3−イルメタノールから始まり、N−ベンジル保護し、アルコールをメシレートに変換すること、
(b)中間体:
を調製するための、メシレートをアジドで置き換えること、
(c)
を調製するための置換アルキンによる環化、
(d)
を調製するための脱ベンジル化、
(e)
を調製するためのカルボン酸アナログをカップリングすること、ならびに
(f)
及び
を調製するための、Boc保護基を除去すること、を含む。
本明細書を解釈する目的のために、以下の定義が適用され、適切な場合はいつでも、単数形で使用される用語は、複数形も含み、逆もまた同様であろう。以下に記載される任意の定義が、参照により本明細書に組み込まれる任意の文書と矛盾する場合、以下に記載される定義が優先するものとする。
〔発明を実施するための形態〕
HL840(
)((R,E)−(1−((1−(3−(1−メチル−1H−ピラゾール−4−イル)アクリロイル)ピペリジン−3−イル)メチル)−1H−1,2,3−トリアゾール−4−イル)メタナミニウム)を同定した(例えば、実施例1〜3を参照のこと)。
それらの薬学的に許容される塩、溶媒和物、及び/またはプロドラッグを含む。
〔実施例〕
HL840は、SE−CRTの相互作用及びシグナル伝達を阻害する。
本明細書で詳細に説明されるように、共有エピトープ(SE)リガンドは、カルレティキュリン(CRT)に結合し、異常な免疫系のシグナル伝達/調節を活性化する。
HL840エナンチオマー固有の効果、
HL840は、ラセミ体として市販されている。HL840のエナンチオマーが効力及び代謝安定性を含む異なる薬理学的特性を示すかどうかを確認するために、実験を実施した。従って、新規合成経路を介して、ラセミ体及び両方の鏡像異性体を合成した(以下の実施例3及び図4を参照のこと)。図3に示されるように、(R)−エナンチオマーは、ラセミHL840の全ての活性(例えば、SE−CRT相互作用及びシグナル伝達の阻害)に関与している。
(R)−HL840及び関連アナログのキラル合成
(R)−HL840(R1=Me、R2=H)の合成が図4に示される。このルートは、アナログ合成に非常に適する。市販のキラルピペリジン−3−イルメタノール2をピラゾールアクリル酸1とカップリングして、アミド3を得た。ピラゾールのための多くの複素環式等価体(例えば、イオキサゾール、オキサゾール)は、適切なアクリル酸位置異性体(例えば、図4の1a)として市販されている。種々の置換アクリル酸を、市販のアルデヒドR1HETCHOから合成することもできる。アルコール3をメシル化して4を得、アジドと置換して、粗5を得た。次に、アジド5は、市販のBocで保護された置換アルキンと共に3+2環化を受け、1,2,3トリアゾール6を得ることができる。標準条件下でのBocの除去により、アナログ7が得られる。アルデヒドを用いる後続の逐次還元的アミノ化により、それぞれアナログ8及び9が得られる。
トリアゾール−メチル−ピペリジニル−ピロリル−プロペノン構造を有し、構造的に類似した小分子は、破骨細胞の形成を阻害する。
実験により、共有エピトープ(SE)−カルレティキュリン(CRT)結合及び/または相互作用のモジュレーターとして機能するトリアゾール−メチル−ピペリジニル−ピロリル−プロペノン構造を有し且つ構造的に類似したさらなる小分子が同定された。
本明細書で言及される特許文書及び科学論文のそれぞれの開示全体が、あらゆる目的で参照により組み込まれる。
本発明は、趣旨またはその本質的な特徴から逸脱することなく、他の特定の形態で実行されてもよい。従って、上述の実施形態は、本明細書に記載の本発明を限定するのではなく、あらゆる点で例示とみなされるべきである。従って、本発明の範囲は、上述の説明よりもむしろ、添付の特許請求の範囲により示され、特許請求の範囲の等価の意味及び範囲内にある全ての変更が、そこに包含されることが意図される。
Claims (20)
- R3が、水素またはフッ素からなる群より選択される、請求項1に記載の化合物。
- 請求項1に記載の化合物を含む、医薬組成物。
- 患者の免疫調節異常を処置、改善、または予防する方法であって。請求項6に記載の医薬組成物を治療有効量、前記患者に投与することを含む、前記方法。
- 前記免疫調節異常が、自己免疫疾患または慢性炎症性疾患である、請求項7に記載の方法。
- 前記自己免疫疾患または慢性炎症性疾患が、関節リウマチである、請求項8に記載の方法。
- 前記処置、改善、または予防が、前記患者の骨びらんを阻害及び/または低減する、請求項9に記載の方法。
- 前記免疫調節異常が、全身性エリテマトーデス、慢性関節リウマチ、I型糖尿病、炎症性腸疾患、胆汁性肝硬変、ブドウ膜炎、多発性硬化症、クローン病、潰瘍性大腸炎、水疱性類天疱瘡、サルコイドーシス、乾癬、自己免疫性筋炎、Wegener肉芽腫症、魚鱗癬、Graves眼症、喘息、臓器または組織の移植、移植により引き起こされる移植片対宿主病、関節リウマチを含む自己免疫症候群、全身性エリテマトーデス、橋本甲状腺炎、多発性硬化症、重症筋無力症、I型糖尿病、ブドウ膜炎、後部ブドウ膜炎、アレルギー性脳脊髄炎、糸球体腎炎、リウマチ熱及び感染後の糸球体腎炎を含む感染後の自己免疫疾患、炎症性及び過剰増殖性皮膚疾患、乾癬、アトピー性皮膚炎、接触性皮膚炎、湿疹性皮膚炎、脂漏性皮膚炎、扁平苔癬、天疱瘡、水疱性類天疱瘡、表皮水疱症、蕁麻疹、血管浮腫、血管炎、紅斑、皮膚好酸球増加症、紅斑性狼瘡、ざ瘡、円形脱毛症、角結膜炎、夏季結膜炎、Behcet病に関連するブドウ膜炎、角膜炎、疱疹性角膜炎、円錐角膜、上皮性角膜ジストロフィー、角膜白斑、眼天疱瘡、Mooren潰瘍、強膜炎、Graves眼症(opthalmopathy)、Vogt−Koyanagi−Harada症候群、サルコイドーシス、花粉症、治療可能な閉塞性気道疾患、気管支喘息、アレルギー性喘息、内因性喘息、外因性喘息、塵埃喘息、慢性または難治性喘息、遅発型喘息及び気道過敏症、気管支炎、胃潰瘍、虚血性疾患及び血栓症によって引き起こされる血管損傷、虚血性腸疾患、炎症性腸疾患、壊死性腸炎、熱傷に関連する腸病変、小児脂肪便症、直腸炎、好酸球性胃腸炎、肥満細胞症、クローン病、潰瘍性大腸炎、片頭痛、鼻炎、湿疹、間質性腎炎、Goodpasture症候群、溶血性尿毒症症候群、糖尿病性腎症、多発性筋炎、Guillain−Barre症候群、Meniere病、多発性神経炎、多発神経炎、単発神経炎、神経根障害、甲状腺機能亢進症、Basedow病、赤芽球癆、無形成性貧血、再生不良性貧血、特発性血小板減少性紫斑病、自己免疫性溶血性貧血、無顆粒球症、悪性貧血、巨赤芽球性貧血、赤血球形成不全、骨粗鬆症、サルコイドーシス、肺線維症、特発性間質性肺炎、皮膚筋炎、尋常性白皮症、尋常性魚鱗癬、光アレルギー性過敏症、皮膚T細胞リンパ腫、動脈硬化、アテローム性動脈硬化症、大動脈炎症候群、結節性多発性動脈炎、心筋症、強皮症、Wegener肉芽腫、Sjogren症候群、脂肪過多、好酸球性筋膜炎;歯肉、歯周組織、歯槽骨、歯のセメント質の病変;糸球体腎炎、脱毛の防止または発毛の提供及び/または発毛及び育毛の促進による男性型脱毛症または老人性脱毛症、筋ジストロフィー、膿皮症及びSezary症候群、Addison病、保存時に発生する臓器の虚血再灌流障害、移植または虚血性疾患、エンドトキシンショック、偽膜性大腸炎、薬物または放射線による大腸炎、虚血性急性腎不全、慢性腎不全、肺酸素または薬物による中毒症、肺がん、肺気腫、白内障、鉄沈着症、網膜色素変性症、老人性黄斑変性症、硝子体瘢痕、角膜アルカリ熱傷、多形滲出性紅斑皮膚炎、線状IgA水疱性皮膚炎及びセメント皮膚炎、歯肉炎、歯周炎、敗血症、膵炎、環境汚染により引き起こされる疾患、老化、発がん、がん腫の転移及び高山病、ヒスタミンまたはロイコトリエン−C.sub.4放出により引き起こされる疾患、Behcet病、自己免疫性肝炎、原発性胆汁性肝硬変、硬化性胆管炎、肝臓部分切除、急性肝壊死、毒素により引き起こされる壊死、ウイルス性肝炎、ショック、または無酸素症、B−ウイルス性肝炎、非A/非B型肝炎、肝硬変、アルコール性肝硬変、肝不全、劇症肝不全、晩発性肝不全、「慢性的急性」肝不全、化学療法効果の増強、サイトメガロウイルス感染症、HCMV感染症、AIDS、がん、老年性認知症、外傷、及び慢性細菌感染症からなる群より選択される、請求項7に記載の方法。
- さらに、1つ以上の抗炎症性及び/または抗リウマチ組成物を前記患者に投与することを含む、請求項7に記載の方法。
- 前記免疫調節異常が、1)関節リウマチ、2)多発性硬化症、3)全身性エリテマトーデス、4)乾癬、5)移植臓器または組織の拒絶反応、6)炎症性腸疾患、ならびに、7)インスリン及び非インスリン依存性糖尿病、からなる群より選択される、請求項7に記載の方法。
- 請求項6に記載の医薬組成物を免疫抑制有効量、前記患者に投与することを含む、免疫抑制剤を必要とする哺乳動物患者の免疫系を抑制する方法。
- 患者の骨びらん及び/または骨量減少を特徴とする疾患または状態を処置、改善、または予防する方法であって、前記骨びらん及び/または骨量減少の疾患または状態を処置、改善、または予防するために有効な量の請求項6に記載の医薬組成物を、前記患者に投与することを含む、前記方法。
- 前記疾患または状態が、関節リウマチ、骨破壊関節炎状態、歯周病、骨粗鬆症、骨髄炎、骨転移、骨折治癒のうちの1つ以上である、請求項15に記載の方法。
- 前記処置、改善、または予防が、前記患者の骨密度、骨量、及び/または骨構造を増強及び/または維持する、請求項15に記載の方法。
- さらに、1つ以上の抗炎症性及び/または抗リウマチ組成物を前記患者に投与することを含む、請求項15に記載の方法。
- 請求項1に記載の化合物及び任意の薬学的に許容される担体を含む薬品、ならびに哺乳動物患者の骨びらん及び/または骨量減少を処置するか、またはこれらの進行を遅延させるための前記薬品の投与のための使用説明書を含む添付文書、を含むキット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762582584P | 2017-11-07 | 2017-11-07 | |
US62/582,584 | 2017-11-07 | ||
PCT/US2018/059623 WO2019094469A1 (en) | 2017-11-07 | 2018-11-07 | Small molecule inhibitors of shared epitope-calreticulin interactions and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2021502361A true JP2021502361A (ja) | 2021-01-28 |
Family
ID=66326814
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020524852A Pending JP2021502361A (ja) | 2017-11-07 | 2018-11-07 | 共有エピトープ−カルレティキュリン相互作用の小分子阻害薬及び使用方法 |
Country Status (9)
Country | Link |
---|---|
US (3) | US10723718B2 (ja) |
EP (1) | EP3706744B1 (ja) |
JP (1) | JP2021502361A (ja) |
KR (1) | KR20200085278A (ja) |
CN (2) | CN111315383B (ja) |
AU (1) | AU2018366022B2 (ja) |
CA (1) | CA3079848A1 (ja) |
MX (2) | MX2020004566A (ja) |
WO (1) | WO2019094469A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3706744B1 (en) * | 2017-11-07 | 2022-08-17 | The Regents of The University of Michigan | Small molecule inhibitors of shared epitope-calreticulin interactions and methods of use |
CN112194719A (zh) * | 2020-09-01 | 2021-01-08 | 中日友好医院(中日友好临床医学研究所) | Crt抗原和mage-a1抗原的制备及其应用 |
CN112125561B (zh) * | 2020-09-18 | 2021-11-02 | 河海大学 | 一种基于植物花粉提取液的水泥基材料调热缓凝剂、制备方法及应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004513063A (ja) * | 1999-04-02 | 2004-04-30 | アボット・ラボラトリーズ | 細胞接着阻害抗炎症および免疫抑制化合物 |
US20050013820A1 (en) * | 2002-06-03 | 2005-01-20 | The Regents Of The University Of Michigan | Methods and compositions for the treatment of MHC-associated conditions |
JP2016539137A (ja) * | 2013-12-05 | 2016-12-15 | ファイザー・インク | ピロロ[2,3−d]ピリミジニル、ピロロ[2,3−b]ピラジニル、およびピロロ[2,3−d]ピリジニルアクリルアミド |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4552891A (en) | 1983-09-13 | 1985-11-12 | Eli Lilly And Company | Benzothiophene derivatives |
GB9026998D0 (en) | 1990-12-12 | 1991-01-30 | Glaxo Group Ltd | Medicaments |
GB9102579D0 (en) | 1991-01-24 | 1991-03-27 | Glaxo Group Ltd | Compositions |
BE1007839A6 (nl) | 1993-12-20 | 1995-10-31 | Merkus Franciscus W H M Prof | Farmaceutische compositie voor de nasale toediening van hydroxocobalamine. |
US5864037A (en) | 1996-06-06 | 1999-01-26 | Euro-Celtique, S.A. | Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity |
US6124319A (en) | 1997-01-21 | 2000-09-26 | Merck & Co., Inc. | 3,3-disubstituted piperidines as modulators of chemokine receptor activity |
US5869479A (en) | 1997-08-14 | 1999-02-09 | Schering Corporation | Treatment of upper airway allergic responses |
US6878700B1 (en) | 1998-12-29 | 2005-04-12 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds |
US7074893B2 (en) | 2002-06-03 | 2006-07-11 | Regents Of The University Of Michigan | Methods and compositions for the treatment of diseases associated with signal transduction aberrations |
US7196078B2 (en) * | 2002-09-04 | 2007-03-27 | Schering Corpoartion | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors |
US20050138290A1 (en) | 2003-12-23 | 2005-06-23 | Intel Corporation | System and method for instruction rescheduling |
EP3706744B1 (en) * | 2017-11-07 | 2022-08-17 | The Regents of The University of Michigan | Small molecule inhibitors of shared epitope-calreticulin interactions and methods of use |
-
2018
- 2018-11-07 EP EP18875370.1A patent/EP3706744B1/en active Active
- 2018-11-07 MX MX2020004566A patent/MX2020004566A/es unknown
- 2018-11-07 KR KR1020207012957A patent/KR20200085278A/ko not_active Application Discontinuation
- 2018-11-07 CN CN201880071416.9A patent/CN111315383B/zh active Active
- 2018-11-07 CA CA3079848A patent/CA3079848A1/en active Pending
- 2018-11-07 WO PCT/US2018/059623 patent/WO2019094469A1/en unknown
- 2018-11-07 AU AU2018366022A patent/AU2018366022B2/en active Active
- 2018-11-07 JP JP2020524852A patent/JP2021502361A/ja active Pending
- 2018-11-07 US US16/183,309 patent/US10723718B2/en active Active
- 2018-11-07 CN CN202311174646.7A patent/CN117304172A/zh active Pending
-
2020
- 2020-06-09 US US16/896,546 patent/US11168071B2/en active Active
- 2020-07-13 MX MX2022016067A patent/MX2022016067A/es unknown
-
2021
- 2021-10-14 US US17/501,572 patent/US11613528B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004513063A (ja) * | 1999-04-02 | 2004-04-30 | アボット・ラボラトリーズ | 細胞接着阻害抗炎症および免疫抑制化合物 |
US20050013820A1 (en) * | 2002-06-03 | 2005-01-20 | The Regents Of The University Of Michigan | Methods and compositions for the treatment of MHC-associated conditions |
JP2016539137A (ja) * | 2013-12-05 | 2016-12-15 | ファイザー・インク | ピロロ[2,3−d]ピリミジニル、ピロロ[2,3−b]ピラジニル、およびピロロ[2,3−d]ピリジニルアクリルアミド |
Non-Patent Citations (1)
Title |
---|
REGISTRY(STN)[ONLINE], JPN7022004044, 18 September 2009 (2009-09-18), ISSN: 0004988885 * |
Also Published As
Publication number | Publication date |
---|---|
EP3706744A4 (en) | 2020-12-09 |
WO2019094469A1 (en) | 2019-05-16 |
MX2020004566A (es) | 2020-08-13 |
CN111315383B (zh) | 2023-09-29 |
US11168071B2 (en) | 2021-11-09 |
AU2018366022B2 (en) | 2024-05-16 |
EP3706744B1 (en) | 2022-08-17 |
US20220106292A1 (en) | 2022-04-07 |
US20190135783A1 (en) | 2019-05-09 |
EP3706744A1 (en) | 2020-09-16 |
US20200299268A1 (en) | 2020-09-24 |
CN117304172A (zh) | 2023-12-29 |
AU2018366022A1 (en) | 2020-04-30 |
US10723718B2 (en) | 2020-07-28 |
KR20200085278A (ko) | 2020-07-14 |
CA3079848A1 (en) | 2019-05-16 |
MX2022016067A (es) | 2023-02-02 |
CN111315383A (zh) | 2020-06-19 |
US11613528B2 (en) | 2023-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11613528B2 (en) | Small molecule inhibitors of shared epitope-calreticulin interactions and methods of use | |
US20220267780A1 (en) | Conjugates of bile acids and their derivatives for active molecules delivery | |
JP2023081969A (ja) | Tlrアゴニストによる呼吸器感染症の治療 | |
JP5785939B2 (ja) | オキサゾリジノン含有二量体化合物、組成物、ならびに作製および使用方法 | |
BR112021000938A2 (pt) | composto sal farmaceuticamente aceitável, tautômero, isômero ou estereoisômero do mesmo, composição farmacêutica e processo para a síntese do dito composto | |
RU2521286C2 (ru) | Модуляторы рецептора сфингозин-1-фосфата (s1p) и их применение для лечения воспаления мышечной ткани | |
JP2008519815A (ja) | 化合物 | |
US20050209141A1 (en) | Mast cell-derived renin | |
CN112638866B (zh) | 索拉非尼衍生物的共晶体及其制备方法 | |
KR20160130853A (ko) | 신경변성 질환을 치료하기 조성물 및 방법 | |
CN114025766A (zh) | 用于抑制gapdh的噁噻嗪化合物 | |
TW201625264A (zh) | 水晶體硬化抑制劑 | |
US11510913B1 (en) | Modulating expression level of a gene encoding an apurinic/apyrimidinic endodeoxyribonuclease protein by treating a human subject with a nitroxide | |
US11672811B2 (en) | Materials and methods for suppressing and/or treating bone related diseases and symptoms | |
US20210308138A1 (en) | Tissue transglutaminase modulators for medicinal use | |
US10251869B2 (en) | Compositions and methods of inhibiting metallo-β-lactamases | |
JP6838743B2 (ja) | 非ペプチド性gapdh凝集阻害剤 | |
WO2002011736A1 (en) | Naadp analogues for modulating t-cell activity | |
WO2021066136A1 (ja) | 筋ジストロフィー治療薬 | |
WO2007148744A1 (ja) | フマル酸誘導体を有効成分として含む角結膜障害の予防または治療剤 | |
JP2001288106A (ja) | 炎症性疾患治療剤 | |
CA3176384A1 (en) | Method of treating ship1-mediated diseases using pelorol derivatives | |
CN116850187A (zh) | Hapalindole在制备抑制肝癌或乳腺癌的药物中的应用 | |
JP2018070538A (ja) | カテプシンk阻害剤を含んでなる骨格筋疾患の予防および/または治療のための医薬組成物 | |
JPH03190822A (ja) | 抗炎症活性を有する新規な製薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210914 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220810 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220823 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221124 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230214 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230614 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20230614 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20230703 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20230908 |